

Hikma remains a constituent of the FTSE4Good Index

London, 15 August 2023 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that it remains a constituent of the FTSE4Good Index Series, affirming its strong environmental, social and governance practices.

The FTSE4Good Index Series was created by the global index and data provider FTSE Russell to highlight companies that demonstrate good sustainability practices and to support investors that wish to align their portfolios with such organisations.

Hikma has been a member of the FTSE4Good Index since 2014. Over this time, Hikma has taken substantial steps forward in integrating sustainability into its corporate strategy and strengthening how it manages key themes including minimising environmental impact, expanding access to medicine and promoting an inclusive and empowering workplace.

Susan Ringdal, EVP, Strategic Planning and Global Affairs for Hikma said, “We are pleased to remain constituents of the FTSE4Good and are proud of the steps we continue to take to act responsibly. Promoting more sustainable business practices remains fundamental to our continued success as an organisation and aligns with our purpose of putting better health within reach, every day.”

For more information on how Hikma acts responsibly, including details of the targets Hikma has set, visit the website or read the Hikma Sustainability Report 2022.

- ENDS -

Enquiries

Hikma (Investors):

Susan Ringdal EVP, Strategic Planning and Global Affairs	+44 (0)20 7399 2760/ +44 (0)7776 477050
Guy Featherstone Associate Director, Investor Relations	+44 (0)20 3892 4389/ +44 (0)7795 896738
Layan Kalisse Senior Associate, Investor Relations	+44 (0)20 7399 2788/ +44 (0)7970 709912

About Hikma

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P and BBB-/positive Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,800 colleagues are helping to shape a healthier world that

hikma.

enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com